Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
Titel:
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
Auteur:
Verstovsek, Srdan Gerds, Aaron T Vannucchi, Alessandro M Al-Ali, Haifa Kathrin Lavie, David Kuykendall, Andrew T Grosicki, Sebastian Iurlo, Alessandra Goh, Yeow Tee Lazaroiu, Mihaela C Egyed, Miklos Fox, Maria Laura McLornan, Donal Perkins, Andrew Yoon, Sung-Soo Gupta, Vikas Kiladjian, Jean-Jacques Granacher, Nikki Lee, Sung-Eun Ocroteala, Luminita Passamonti, Francesco Harrison, Claire N Klencke, Barbara J Ro, Sunhee Donahue, Rafe Kawashima, Jun Mesa, Ruben